Patents by Inventor Gregory R. Ott

Gregory R. Ott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidinone derivatives as CDC7 inhibitors
    Patent number: 11766434
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: September 26, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220306651
    Abstract: The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield, John Andrew Christopher, Andrea Bortolato
  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220251110
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS
    Publication number: 20220079942
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: April 29, 2021
    Publication date: March 17, 2022
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Pyrimidinone derivatives as Cdc7 inhibitors
    Patent number: 11020396
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 1, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10954251
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: March 23, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • Preparation and uses of pyrimidinone derivatives
    Patent number: 10919896
    Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 16, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J. T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10632119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 28, 2020
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE
    Publication number: 20200123157
    Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 23, 2020
    Inventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J.T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
  • PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS
    Publication number: 20190336502
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: November 7, 2017
    Publication date: November 7, 2019
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Fused Bicyclic 2,4-Diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20190328735
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 31, 2019
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Prodrugs of Chlorokynurenines
    Publication number: 20190308934
    Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: Ralph Laufer, Gregory R. Ott
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 10414763
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: September 17, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J T Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
    Publication number: 20190106433
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Inventors: Bruce D. DORSEY, Keith S. LEARN, Emma L. MORRIS, Gregory R. OTT, Jonathan R.A. ROFFEY, Christelle N. SOUDY, Jason C. WAGNER
  • Thienopyrimidine inhibitors of atypical protein kinase C
    Patent number: 10183950
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 22, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Keith S. Learn, Emma L. Morris, Gregory R. Ott, Jonathan R. A. Roffey, Christelle N. Soudy, Jason C. Wagner
  • PRODRUGS OF CHLOROKYNURENINES
    Publication number: 20180327351
    Abstract: The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined herein. Also provided are methods of preparing and using these prodrugs.
    Type: Application
    Filed: September 8, 2016
    Publication date: November 15, 2018
    Inventors: Ralph LAUFER, Gregory R. OTT
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10111872
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 30, 2018
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
    Publication number: 20180305298
    Abstract: Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, including neuropsychiatric disorders such as depression, epilepsy, schizophrenia, and Huntington's Disease, and use of said deuterated chlorokynurenines are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: October 25, 2018
    Inventors: Gregory R. OTT, Chengzhi ZHANG, Ralph LAUFER
  • Azaquinazoline inhibitors of Atypical protein Kinase C
    Patent number: 9914730
    Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J Dugan, Katherine M. Fowler, Robert L Hudkins, Eugen F. Mesaros, Nathaniel J. T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 9896446
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 20, 2018
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R. A. Roffey, Nathaniel J. T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye